Press Releases
Date picker
Category
Results per page
Kancera updates the clinical development plan for KAND567
This is a translation of a press release in Swedish published 2019-11-21 Kancera AB (Nasdaq First North Growth Market: KAN) today announces that the company intends to complete the final…
Kancera unveils preclinical findings for its lead compound, KAND567, at world’s largest cardiovascular conference
Kancera AB (Nasdaq First North: KAN) announces the first public presentation of data for KAND567, its fractalkine receptor antagonist, in preclinical models of cardiovascular disease and its predicted translation to…
Kancera develops the dosing strategy for KAND567 which means an added delay of the phase 1b study
Kancera today announces that a further developed dosing strategy is intended to be tested for the treatment with KAND567. The reason is that the modified intravenous dosing studied in the…
Interim report for the second quarter 2019, 1 January – 30 June 2019
Regulatory
Second quarter in brief1 April – 30 June 2019 Net sales for the period (January to June) amounted to SEK 3,1 Million (0 Million) of which the second quarter contributed…
Kancera provides an operational update and announces an issue of shares in accordance with the agreement with Global Corporate Finance
Kancera AB (Nasdaq First North: KAN) announces that the company's clinical Phase Ib study according to plan will start again today. The aim is to report the study in November…
Kancera completes the third and final installment for the Fractalkine project
Kancera today announces that the third installment for the Fractalkine project and KAND567 is carried out according to the acquisition agreement. The payment that was activated in connection with the…
Kancera provides operational update and announces issue of shares according to agreement with Global Corporate Finance
Kancera AB (Nasdaq First North: CAN) today announced that two patent applications within the fractalkine project are now entering international phase and that the agreement with US Global Corporate Finance…
Kancera announces positive interim results and a minor delay in ongoing Phase Ib clinical study of KAND567
Kancera today announces positive interim results in the ongoing Phase Ib study of KAND567, which aims to study intravenous infusion of the drug candidate to healthy subjects. The first exploratory…
Kancera announces start of clinical Phase Ib study of KAND567
The clinical Phase Ib study of intravenous administered KAND567 has started and is planned to be completed during the third quarter of 2019. KAND567 has previously been shown to be…
INTERIM REPORT FOR THE FIRST QUARTER 2019, 1 January – 31 March 2019
Regulatory
First quarter in brief1 January – 31 March 2019 Net sales for the period (January to March) amounted to SEK 0.0 million (SEK 0.0 million) R&D costs for the period…